Jaguar Health Stock Plunges Wednesday: What's Happening?

Jaguar Health Inc. (NASDAQ: JAGX) experienced a significant stock decline of 64.16%, dropping to $12.35, following a massive rally of over 1,100% to $34.46 on Tuesday, which was driven by FDA regulatory fee waivers for its lead drug, Mytesi. The stock's volatility is attributed to a recent 1-for-15 reverse stock split that limited the public float to approximately 520,088 shares. Additionally, the company faces ongoing financial pressures, including a second-quarter net loss of $12.7 million and over $25 million in current liabilities, prompting concerns about potential capital-raising efforts.